Pruritus in primary myelofibrosis: Clinical and laboratory correlates
暂无分享,去创建一个
[1] T. Barbui,et al. Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis. , 2011, Blood.
[2] A. Tefferi,et al. Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] Catriona Jamieson,et al. Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] Ayalew Tefferi,et al. Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] F. Passamonti,et al. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] Ayalew Tefferi,et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. , 2010, The New England journal of medicine.
[7] A. Tefferi,et al. Polycythemia vera‐associated pruritus and its management , 2010, European journal of clinical investigation.
[8] T. Barbui,et al. A pilot study of the Histone‐Deacetylase inhibitor Givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms , 2010, British journal of haematology.
[9] D. Gilliland,et al. IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis , 2010, Leukemia.
[10] Z. Estrov,et al. Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. , 2010, Blood.
[11] P. Guglielmelli,et al. The JAK2V617 mutation induces constitutive activation and agonist hypersensitivity in basophils from patients with polycythemia vera , 2009, Haematologica.
[12] A. Tefferi,et al. Pruritus in polycythemia vera is associated with a lower risk of arterial thrombosis , 2008, American journal of hematology.
[13] R. Mesa,et al. Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival , 2008, Leukemia.
[14] Paola Guglielmelli,et al. JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis. , 2007, Blood.
[15] Paola Guglielmelli,et al. Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia. , 2007, Blood.
[16] J. Sloan,et al. The Burden of Fatigue and Quality of Life in Myeloproliferative Disorders (MPDs): An International Internet Based Survey of 1179 MPD Patients. , 2006 .
[17] D. Gilliland,et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. , 2006, Blood.
[18] D. Steensma,et al. The JAK2V617F tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates , 2005 .
[19] D. Steensma,et al. The JAK2(V617F) tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates. , 2005, British journal of haematology.
[20] A. Tefferi,et al. Pruritus in polycythaemia vera: prevalence, laboratory correlates and management , 2001, British journal of haematology.
[21] L. Wasserman,et al. A study of histamine in myeloproliferative disease. , 1966, Blood.